Molecular Cardiology

Lead Research Organisation: MRC London Institute of Medical Sciences

Abstract

Heart attacks are a common form of death, which can occur at the time of the heart attack or in the years that follow, due to heart failure. The focus of our Group is to discover ways of reducing the size of a heart attack and to prevent people from developing heart failure. Our Group uses the results of the human genome project and specialised genetic resources to identify the mechanisms controlling heart attacks with a view to developing new treatments for these common form of heart disease.

Technical Summary

In the UK, approximately 150,000 people a year suffer from a myocardial infarction (MI), for which left ventricular hypertrophy is a major risk factor. The molecular mechanisms controlling the interplay between heart growth, infarct size and post-MI heart failure are poorly understood and are a major focus of the group. ||To address the mechanisms controlling heart growth, we have applied integrated genetic, genomic and functional studies in the rat and mouse and translated our findings to human populations. Our work has identified the genetic control points for thousands of genes in the rodent heart, which were used to identify an extra-cellular matrix protein, Ogn, as a primary determinant of left ventricular mass in mice, rats and humans. Identification of genes, such as Ogn, may lead to new treatments for human heart disease.||In other studies we have used cardiac magnetic resonance imaging guided human heart biopsies to determine the activity of key protein kinases in the hearts of patients with post-MI heart failure. These kinase studies have revealed unappreciated perturbations of the insulin signalling module in heart and skeletal muscle, which have implications for the treatment of diabetes and heart failure.||Overall, our data demonstrate the power of cutting-edge imaging, genomic and molecular approaches in rodents and humans, which can be used to identify robust candidates for disease pathogenesis with a view to developing new molecular insights and treatments for human heart disease.

Publications

10 25 50

publication icon
Biffi C (2018) Three-dimensional cardiovascular imaging-genetics: a mass univariate framework. in Bioinformatics (Oxford, England)

publication icon
Cook SA (2009) Are transgenic mice the 'alkahest' to understanding myocardial hypertrophy and failure? in Journal of molecular and cellular cardiology

publication icon
Corden B (2013) Body fat is associated with reduced aortic stiffness until middle age. in Hypertension (Dallas, Tex. : 1979)

publication icon
Corden B (2016) Relationship between body composition and left ventricular geometry using three dimensional cardiovascular magnetic resonance. in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance

 
Description BHF Clinical PhD Fellowship
Amount £192,370 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2010 
End 04/2012
 
Description BHF Clinical PhD Fellowship
Amount £166,344 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2008 
End 11/2011
 
Description BHF Fellowship
Amount £192,370 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2007 
End 11/2011
 
Description BHF Project Grant
Amount £154,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2007 
End 12/2011
 
Description BHF Project Grant
Amount £163,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2008 
End 05/2010
 
Description Capital Equipment Grant
Amount £850,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 12/2009 
End 11/2011
 
Description Clinical PhD
Amount £195,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2008 
End 12/2011
 
Description Drugs Discovery Grant
Amount £200,000 (GBP)
Organisation MRC-Technology 
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 12/2011
 
Description EC FP7 funding
Amount £400,000 (GBP)
Organisation European Commission 
Department Seventh Framework Programme (FP7)
Sector Public
Country European Union (EU)
Start 01/2010 
End 12/2014
 
Description European Commission/Max Delbreuk Centrum Fuer Molekulare Medizin
Amount £498,376 (GBP)
Organisation Helmholtz Association of German Research Centres 
Department The Max Delbrück Center for Molecular Medicine (MDC)
Sector Academic/University
Country Germany
Start 04/2010 
End 09/2014
 
Description Fondation Leducq, Transatlantic Network of Excellence
Amount £320,000 (GBP)
Organisation Transatlantic Networks of Excellence in Cardiovascular Research Program 
Sector Academic/University
Country France
Start 01/2007 
End 12/2011
 
Description Imperial College Healthcare NHS Trust (BRC)
Amount £381,634 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 05/2010 
End 04/2012
 
Description Leducq Transatlantic Network of Excellence Program
Amount £6,000,000 (GBP)
Organisation Transatlantic Networks of Excellence in Cardiovascular Research Program 
Sector Academic/University
Country France
Start 09/2011 
End 09/2017
 
Description NIHR, Clinical Scientist Award
Amount £634,532 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2009 
End 12/2011
 
Description National Institute for Health Research
Amount £10,000,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2012 
End 04/2017
 
Description UK Biomedic Research Unit
Amount £10,000,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 01/2012 
End 01/2017
 
Description UK Charity
Amount £1,000,624 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2010 
End 10/2013
 
Description UK-Based Charity Fellowship
Amount £224,864 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2010 
End 07/2013
 
Description External 
Organisation Academy of Sciences of the Czech Republic
Country Czech Republic 
Sector Learned Society 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation Agilent Technologies
Country United States 
Sector Private 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation Helmholtz Association of German Research Centres
Department The Max Delbrück Center for Molecular Medicine (MDC)
Country Germany 
Sector Academic/University 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation Life Technologies
Country Global 
Sector Private 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation Maastricht University (UM)
Country Netherlands 
Sector Academic/University 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation University of Lleida
Country Spain 
Sector Academic/University 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description External 
Organisation University of Wisconsin-Madison
Country United States 
Sector Academic/University 
PI Contribution project management
Collaborator Contribution data and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsdata and reagentsClinical TrialsNext Generation SequencingDevelopment of clinical diagnosics
Impact 18443592, 15711544
Start Year 2006
 
Description MRC-CSC 
Organisation Medical Research Council (MRC)
Department MRC Clinical Sciences Centre (CSC)
Country United Kingdom 
Sector Academic/University 
PI Contribution data, reagents, project management
Collaborator Contribution data and reagentsdata and reagentsintellectual input to project development
Impact 18443592, 15711544
 
Description MRC-CSC 
Organisation Medical Research Council (MRC)
Department MRC Clinical Sciences Centre (CSC)
Country United Kingdom 
Sector Academic/University 
PI Contribution data, reagents, project management
Collaborator Contribution data and reagentsdata and reagentsintellectual input to project development
Impact 18443592, 15711544
 
Description MRC-CSC 
Organisation Medical Research Council (MRC)
Department MRC Clinical Sciences Centre (CSC)
Country United Kingdom 
Sector Academic/University 
PI Contribution data, reagents, project management
Collaborator Contribution data and reagentsdata and reagentsintellectual input to project development
Impact 18443592, 15711544
 
Title A813/2250. Endonuclease G 
Description Endonuclease G: a new target for preventing adverse remodelling and heart failure 
IP Reference WO2011018667 
Protection Patent granted
Year Protection Granted 2011
Licensed No
Impact Endonuclease G inhibition for heart failure
 
Title EBI2 in inflammation 
Description Ebi2 regulates cross-tissue inflammation 
IP Reference Insufficient Information 
Protection Patent granted
Year Protection Granted
Licensed No
Impact manuscript in Nature 2010
 
Description Association of Physicians Annual Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Participating in meeting

N/A
Year(s) Of Engagement Activity 2011
 
Description CNIC Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description ESC - Heart Failure 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description ESC Annual Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description Euratrans Annual Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description ISHR Meeing 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Chair and Speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Primary Audience Health professionals
Results and Impact Cardiac Disease, Development, Regeneratation and repair

Talk Titled "Genomic approaches to heart disease"
Year(s) Of Engagement Activity 2009
 
Description Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Primary Audience Health professionals
Results and Impact Integrative Genomics Study

Talk title:
Year(s) Of Engagement Activity 2009
 
Description Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Primary Audience Health professionals
Results and Impact Heart Failure Researh Winter Meeting

Talk title: "Osteoglycin in the regulation of left ventricular mass".
Year(s) Of Engagement Activity 2009
 
Description Invited Speaker 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Primary Audience Health professionals
Results and Impact Heart Failure meeting - "Surfing the data tsunami: a systems biology approach".

Talk title: Quantitive trait analysis for determinants of left ventricular mass"
Year(s) Of Engagement Activity 2009
 
Description Keystone Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited Speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description Leducq Annual Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Invited speaker

N/A
Year(s) Of Engagement Activity 2011
 
Description Welcome Trust Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact Abstract/Poster presentation

N/A
Year(s) Of Engagement Activity 2011